EXASライブシグナル | Getagraph.comで利益を最大化

売る 192 min ago

@ $59.37

発行日: 29 4月 2024 @ 22:32

リターン: 0.90%

前回のシグナル: 4月 27 - 01:30

前回のシグナル: 買う

リターン: 0.53 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:45):

Stats
本日の出来高	970 709
平均出来高	2.50M
時価総額	10.87B
EPS	$0 ( 2024-02-21 )
次の収益日	( $-0.500 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-53.01
ATR14	$1.700 (2.84%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Condella Sarah	Sell	2 000	Common Stock
2024-04-02	Baranick Brian	Sell	924	Common Stock
2024-03-28	Condella Sarah	Sell	2 000	Common Stock
2024-02-29	Orville Jacob A	Buy	4 724	Common Stock
2024-03-01	Orville Jacob A	Sell	2 154	Common Stock

INSIDER POWER
36.33
Last 100 transactions
Buy: 542 709 \| Sell: 252 987

ボリューム相関

長: -0.22 (neutral)

短: 0.50 (neutral)

Signal:(60) Neutral

Exact Sciences Corp 相関

10 最も正の相関
AVEO	0.942
ITMR	0.941
HZNP	0.928
LUNA	0.926
WLFC	0.925
MLCO	0.923
FCBP	0.922
NWLI	0.92
OBAS	0.916
NWFL	0.914

10 最も負の相関
GOSS	-0.97
VS	-0.951
XFOR	-0.95
GROM	-0.938
TOPS	-0.933
USEG	-0.932
QTEK	-0.931
TRVN	-0.931
SG	-0.93
THTX	-0.929

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Exact Sciences Corp 相関 - 通貨/商品

0.40
( neutral )

0.04
( neutral )

0.00
( neutral )

0.01
( neutral )

-0.69
( moderate negative )

-0.50
( neutral )

Exact Sciences Corp 財務諸表

Annual	2023
収益:	$2.50B
総利益:	$1.85B (73.83 %)
EPS:	$-1.130

FY	2023
収益:	$2.50B
総利益:	$1.85B (73.83 %)
EPS:	$-1.130

FY	2022
収益:	$2.08B
総利益:	$1.51B (72.44 %)
EPS:	$-3.54

FY	2021
収益:	$1.77B
総利益:	$1.31B (74.04 %)
EPS:	$-3.48

Financial Reports:

No articles found.

Exact Sciences Corp

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.